Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma.

Mitchell EversMarjolein StipKaylee KellerHanneke WillemenMaaike NederendMarco JansenChilam ChanKevin BuddingStefan NierkensThomas ValeriusFriederike Meyer-WentrupNiels EijkelkampJeanette H W Leusen

Published in: Journal for immunotherapy of cancer (2022)

Our results indicate that employing IgA GD2 as a novel isotype has two major benefits: it halts antibody-induced excruciating pain and improves neutrophil-mediated lysis of neuroblastoma. Thus, we postulate that patients with high-risk neuroblastoma would strongly benefit from IgA GD2 therapy.

Keyphrases

chronic pain
pain management
neuropathic pain
high glucose
cell therapy
drug induced
mesenchymal stem cells
spinal cord
oxidative stress
combination therapy
bone marrow
smoking cessation